Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-401 in AML and MDS
NCT00397579Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- May 2013
- Primary completion
- Jul 2017
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of tagraxofusp in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by UT Southwestern Medical Center. Started May 2013; status: completed.
02
Drugs
tagraxofusp
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT00397579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397579.